Uncategorized

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors and other important players in the biotech industry to take their business to the next level. Link to the article

World Lupus Day was celebrated on 10th May. At Inhibitec we were very proud to share our progress on the effects of BAMBI deficiency in the development of Lupus during the Annual IMMUNOLOGY 2023 conference held in Washington DC.

Inhibitec’ s team had the privilege to participate in BIOSPAIN 2023, one of the main international biotechnology events in southern Europe, held in Barcelona. This was a dynamic conference marked by numerous meetings we had which offered the great opportunity to share our innovative therapy for Psoriatic Arthritis with potential investors and collaborators. This platform

Inhibitec has been officially recognized by ENISA (Empresa Nacional de Innovacion, S.A) as an outstanding emerging company, being the first to obtain this certificate in Cantabria. This recognition confirms Inhibitec’s commitment and potential in the field of innovation and technology, solidifying its position as a reference point in the region. For more details about this

Towards a novel disruptive therapy in autoimmune disease We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.  A significant number of psoriatic patients with severe disease do not respond to existing therapies.